Company news

Vivani Medical, Inc. news in 2024

Vivani Medical, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

December 18, 2024

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

December 3, 2024

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

November 12, 2024

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

October 21, 2024

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

September 25, 2024

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

September 22, 2024

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

September 3, 2024

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

August 27, 2024

Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results

August 12, 2024

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115

July 10, 2024

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

June 12, 2024

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

May 27, 2024

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

May 12, 2024

Vivani Medical to Present at TIDES Conference 2024

May 8, 2024

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 25, 2024

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

March 5, 2024

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

February 29, 2024

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

February 27, 2024

Decks in 2024